Medical insurance has been removed for 20 billion resistance;

In the past week, the epidemic dissemination caused by the Beijing bar has been controlled. As of 24:00 on June 18, except for a new case of an infection of a new soil, there was no case of social infection, and the epidemic prevention and control approached stable.

Cases of acne cases that are constantly emerging around the world and severe acute hepatitis cases of unknown children. Although there are no two cases in China, relevant departments have successively issued a guide to the two diseases, and have begun to attach importance to the prevention and treatment of the two new diffusion diseases.

In the past week, many executives have submitted resignation letter from Wanchun Pharmaceutical. This company has not yet had commercial products, and its representative products are Ponablin. Earlier, in order to obtain the rights and interests of the development and commercialization of the drug in China, Hengrui Pharmaceutical was willing to generate 1.4 billion high prices.

More information, sort out as follows:

Heavy policy

1. Medical Insurance has pre -allocated 20 billion yuan this year's special fund to resist disease

On June 17, the Journalism Office of the State Council held a routine briefing of the State Council policies on the help of the people in need.

When reporting the prevention and control of the epidemic and medical treatment since this year, Chen Jinfu, deputy director of the National Medical Insurance, said that since the epidemic, the relevant departments have pre -allocated 20 billion special funds to ensure that patients with new crown pneumonia are used to seek medical treatment. As of now, there are no situations that affect patient treatment and medical treatment due to expenses.

At the same time, based on the "dynamic clearing zero" general policy, multiple rounds of consultation reduces vaccine and nucleic acid testing prices. At present, the active vaccine has dropped to less than 20 yuan per dose, and the price of vaccine on other technical routes is also declining simultaneously; nucleic acid detection has dropped to a single test of no more than 16 yuan, the mixed examination does not exceed 5 yuan, and the large -scale nucleic acid test does not exceed 3.5 Yuan.

In addition, in the adjustment of the medical insurance directory, Chen Jinfu proposed the concept of "250, 50%, and 30 billion". The negotiations are included in the scope of medical insurance payment, involving a total of 250 varieties, with an average price reduction by 50%. According to the calculation of clinical dosage, the total burden of 310 billion yuan in the masses was reduced.

2. Monkey acne and unknown causes of children's acute hepatitis treatment guidelines have been introduced one after another

On June 14, the State Health and Health Commission Medical and Health Management Bureau released the "Monkey Acne Diagnosis and Treatment (2022 Edition)", which requires the health administrative departments and traditional Chinese medicine management departments at all levels to attach great importance to the training of monkey acne diagnosis and treatment. Do a good case report.

On June 16, the Health Commission's "Guidelines for the Diagnosis and Treatment of Severe Acute Hepatitis for Children (Trial)", which required health departments at all levels to strengthen the early identification and standardized diagnosis and treatment of diseases, and fully improve the effect of treatment.

Since the beginning of this year, severe acute hepatitis of children with acne and unknown causes has become two diseases that have been popular in many places around the world after new crown pneumonia, which has caused global panic. However, there are no confirmed cases in the country in China.

3. Two nucleic acid testing agencies are included in the list of serious illegal creditburn

This week, according to the national corporate credit information publicity system and market supervision news, Beijing Pushi Medical Inspection Labs Co., Ltd. and Beijing Golden League Medical Inspection Laboratory Co., Ltd. were included in the list of serious violations of the law. At the same time, both laboratories were revoked "Professional License of Medical Institutions".

According to previous reports, the two laboratories have survived by personal profit, affecting the accuracy of nucleic acid detection.

Industry affairs

1. Beida Pharmaceutical Boss Personal Personal Out of 1 billion increases his own shares

On June 13, Beida Pharmaceutical issued an announcement that the company will raise funds for not exceeding 1 billion yuan in the form of issuing shares to a specific opponent to develop its Puzhou Innovation Pharmaceutical Industrialization Base Project and supplementary funds. The target of the fixed increase is Ding Liman, the company's actual controller.

Before the decision -making increase, Ding Lingming directly held 0.2%of Beida Pharmaceutical's shares, coupled with indirectly controlled 22.8%of the shares, and controlled 23.01%of Beida Pharmaceutical's shares. After the fixed increase was completed, Ding Liming controlled 27.54%of the shares of the company.

According to the announcement, Ding Liming shall not be transferred 18 months after the subscription. As of the announcement, Beda Pharmaceutical's stock price rose from 50.1 yuan to 56.1 yuan, an increase of 11.98%.

2. Novarton's highest global profit company last year

On June 14, the international medical industry media Fiere Pharma website announced the profitability of major pharmaceutical companies around the world in 2021.

Among them, Nuohua Pharmaceutical's annual revenue was US $ 52.88 billion, and 812.9 billion U.S. dollars in Pfizer and 93.78 billion yuan from Johnson & Johnson. However, with a net profit of US $ 24.02 billion, it became the highest net profit in 2021. According to the analysis of Fiere Pharma, the high profits of Novarty Pharmaceutical may be related to the $ 14.6 billion Roche shares it sold.

The overview of the top ten pharmaceutical companies of the specific profit is as follows:

3. Wanchun Medicine multiple executives resign

On June 14, Wan Chun Pharmaceutical announced that Dr. Daniel L.zabrowski, a member of the company's board of directors and the compensation member of the board of directors, submitted his resignation letter; at the same time, Dr. Jeffrey Vacirca and Dr. Mark Santos also told the company that he would resign.

In addition to the three executives left within one day, Elizabeth Czrepak, chief financial officer and executive vice president of Wanchun Pharmaceuticals in April this year, resigned; Schooey also submitted a dictionary. Wanchun Pharmaceutical has no commercial products at present, and its representative product Pu Nablin has obtained the "breakthrough therapy" in China and the United States. In August 2021, Hengrui Medicine obtained the joint development and commercialization of the drug in China for 1.4 billion yuan. However, the listing application of Punblin was rejected by the FDA in 2021.

4. In the FDA required recall sequencing by FDA

On June 13, FDA released news that due to the security vulnerabilities of the network system existing in the instrument, it was required to recall the two gene sequencers of the NEXTSEQ 550DX and MISEQDX in the world, a total of 1813 units.

On June 14, Yina's official website responded to the matter: the China Pharmaceutical Supervision Bureau and the Shanghai Pharmaceutical Supervision Bureau had been notified to communicate. The company has issued a notice to Chinese customers in early May and launched the corresponding on -site software upgrade measures in China (does not involve physical recalls). As of the announcement, the live software upgrades of Chinese customers have basically been completed.

New drug inventory

1.BMS Poor Pharmaceutical China Approval China

On June 14, Beltay Schimi Bao announced that its self-developed product injection was approved for listing in China in China. For treatment, it is necessary to regularly infusion of red blood cells and red blood cell infusion ≤15 units 1/24 weeks. Anemia adult patients. This is the world's first and only red blood cell mature agent.

Compared with traditional therapy, Ratsp is expected to reduce the blood transfusion burden of related patients and reduce complications caused by blood transfusion.

2. Another Alzheimer's Diseases failed

On June 16, Roche and Alzheimer's Institute jointly stated that their research product Crenezumab was in the clinical clinical clinical clinical clinical treatment of Alzheimer's disease. Statistical significance has failed to reach the main research end.

Crenezumab is an Aβ monoclonal drug. It is a drug in the latter's pipeline after Roche acquires the genes. In addition to Crenezumab, Roche also has a drug GANTENERUMAB clinically in clinical practice and is expected to disclose the results of the phase III clinical research in the fourth quarter of 2022.

At this point, another giant is Alzheimer.

3. Fuhong Hanlin authorized two similar medicines to Ogaron

On June 13, Fuhong Hanlin issued an announcement that the company had reached cooperation and licensed it to HLX11 and HLX14 in the global market business rights in mainland China, Hong Kong, Macao and Taiwan.

HLX11 is a pharmaceutical drug similar to Puffyzumab, which is planned to treat early breast cancer and metastatic breast cancer. It is currently in phase III clinical; HLX14 is a similar drug of Diushan, which is planned to treat high -risk treatment for high risks Fracture risk of female postmenopausal osteoporosis and other indications, the drug will recently enter Phase III clinical.

According to the cooperation agreement, Ogaron will pay Fuhong Hanlin to pay a down payment of $ 70 million, and the subsequent payments can reach up to 538 million yuan. However, the agreement stipulates that Ogaron has the right to end related cooperation at any time before the success of the HLX14 III research. At that time, Fuhong Hanlin will return to HLX14 related funds in full.

Writing | Nicotinamide

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

- END -